Answers are grounded in this paper and cite their sources.
A machine-learning study demonstrates identification of tumor-reactive gamma delta T cells in cancer patients, suggesting their expansion serves as an early therapeutic biomarker.
γδ T cells are becoming increasingly appreciated for their antitumour capacity and role in mediating responses to immune checkpoint blockade1–3. Unlike classical αβ T cells, the degree to which γδ T cells rely on their T cell receptors (TCRs) to induce antitumour responses remains unclear. The challenge of distinguishing γδ T cells with tumour-reactive TCRs from bystander γδ T cells limits our understanding of tumour-reactive γδ T cell biology and the translation of their TCRs into immunotherapeutics. Here we present PreGame, a machine-learning algorithm capable of identifying tumour-reactive γδ T cells from single-cell CITE sequencing data. We use PreGame to identify tumour-reactive γδ T cells from patients with multiple myeloma or other solid cancers, and confirm the specificity of their TCRs to tumour cells. Clinically, we demonstrate that expansion of tumour-reactive γδ T cells is an early biomarker of response in patients with multiple myeloma receiving combination therapy with belantamab mafodotin. We also identify a γδ TCR epitope in the ubiquitously expressed HLA-C protein and a logic gate that enables tumour immunosurveillance. Thus, PreGame is a versatile tool that can accelerate our understanding of γδ T cell biology and facilitate the translation of γδ TCRs into universal therapeutics. A machine-learning algorithm, PreGame, is developed to identify tumour-reactive γδ T cells from single-cell CITE sequencing data, and expansion of this cell population can be used as a biomarker of therapeutic response.
No takes yet. Share an insight, caveat, or question.
Paul et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: